The long non-coding RNA NKILA inhibits the invasion-metastasis cascade of malignant melanoma via the regulation of NF-κB

American Journal of Cancer Research

Volumn 7, Issue 1, 2017, Pages 28-40

  Bian, Donghui ^a   Gao, Cong ^b   Bao, Kai ^b   Song, Guodong ^b  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

LncRNA NKILA; Melanoma; Metastasis; NF B

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONG UNTRANSLATED RNA; NKILA PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; METASTASIS; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REGULATORY MECHANISM; TUMOR INVASION;

EID: 85009865425     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-386.
3. Coory M, Baade P, Aitken J, Smithers M, McLeod GR and Ring I. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control 2006; 17: 21-27.
4. Holterhues C, Vries E, Louwman MW, Koljenovic S and Nijsten T. Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. J Invest Dermatol 2010; 130: 1807-1812.
5. Downing A, Newton-Bishop JA and Forman D. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England incidence, mortality and survival in relation to stage of disease, 1993-2003. Br J Cancer 2006; 95: 91-95.
6. Mansson-Brahme E, Johansson H, Larsson O, Rutqvist LE and Ringborg U. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994. Acta Oncol 2002; 41: 138-146.
7. Hall HI, Miller DR, Rogers JD and Bewerse B. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999; 40: 35-42.
8. Bulliard JL, Cox B and Semenciw R. Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969-93. Cancer Causes Control 1999; 10: 407-416.
9. Tryggvadottir L, Gislum M, Hakulinen T, Klint A, Engholm G, Storm HH and Bray F. Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010; 49: 665-672.
10. Garbe C and Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27: 3-9.
11. Rincic M, Iourov IY and Liehr T. Thoughts about SLC16A2, TSIX and XIST gene like sites in the human genome and a potential role in cellular chromosome counting. Mol Cytogenet 2016; 9: 56.
12. Chakravarty D, Sboner A, Nair SS, Gianno-Poulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O and Rubin MA. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun 2014; 5: 5383.
13. Ying L, Chen Q, Wang Y, Zhou Z, Huang Y and Qiu F. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst 2012; 8: 2289-2294.
14. Feil R, Walter J, Allen ND and Reik W. Develop-mental control of allelic methylation in the imprinted mouse Igf2 and H19 genes. Develop-ment 1994; 120: 2933-2943.
15. Li H, Yu B, Li J, Su L, Yan M, Zhu Z and Liu B. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 2014; 5: 2318-2329.
16. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhattar R, Gingeras TR, Hubbard TJ, Notredame C, Harrow J and Guigo R. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012; 22: 1775-1789.
17. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74.
18. Guttman M and Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature 2012; 482: 339-346.
19. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Morales DR, Thomas K, Presser A, Bernstein BE and van Oudenaarden A. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A 2009; 106: 11667-11672.
20. Tsai MC, Spitale RC and Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 2011; 71: 3-7.
21. Sen R and Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986. 46: 705-716. J Immunol 2006; 177: 7485-7496.
22. Sen R and Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705-716.
23. May MJ and Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998; 19: 80-88.
24. Hoesel B and Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013; 12: 86.
25. Dijkstra JM and Alexander DB. The "NF-κB interacting long noncoding RNA" (NKILA) transcript is antisense to cancer-associated gene PMEPA1. F1000Res 2015; 4: 96.
26. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, Lin L, Yao H, Su F, Li D, Zeng M and Song E. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell 2015; 27: 370-381.
27. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J and Kung HF. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007; 46: 200-208.
28. Jiang L, Lai YK, Zhang J, Wang H, Lin MC, He ML and Kung HF. Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis. Mol Med 2011; 17: 709-716.
29. Jiao C, Song Z, Chen J, Zhong J, Cai W, Tian S, Chen S, Yi Y and Xiao Y. lncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer. Oncol Rep 2016; 36: 2960-2966.
30. Bida O, Gidoni M, Ideses D, Efroni S and Ginsberg D. A novel mitosis-associated lncRNA, MA-linc1, is required for cell cycle progression and sensitizes cancer cells to paclitaxel. Oncotarget 2015; 6: 27880-27890.
31. Iguchi T, Uchi R, Nambara S, Saito T, Komatsu H, Hirata H, Ueda M, Sakimura S, Takano Y, Kurashige J, Shinden Y, Eguchi H, Sugimachi K, Maehara Y and Mimori K. A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Res 2015; 35: 1385-1388.
32. Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, Carley A, Niknafs YS, Sahu A, Han S, Ma T, Liu M, Asangani IA, Jing X, Cao X, Dhanasekaran SM, Robinson DR, Feng FY and Chinnaiyan AM. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res 2014; 12: 1081-1087.
33. Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM and Feng FY. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun 2016; 7: 12791.
34. Misawa A, Takayama K, Urano T and Inoue S. Androgen-induced long noncoding RNA (lncRNA) SOCS2-AS1 promotes cell growth and inhibits apoptosis in prostate cancer cells. J Biol Chem 2016; 291: 17861-17880.
35. Huang W, Cui X, Chen J, Feng Y, Song E, Li J and Liu Y. Long non-coding RNA NKILA inhibits migration and invasion of tongue squamous cell carcinoma cells via suppressing epithelial-mesenchymal transition. Oncotarget 2016; [Epub ahead of print].
36. Xia Y, Shen S and Verma IM. NF-kappaB, an active player in human cancers. Cancer Immunol Res 2014; 2: 823-830.
37. Viennois E, Chen F and Merlin D. NF-kappaB pathway in colitis-associated cancers. Transl Gastrointest Cancer 2013; 2: 21-29.
38. Meng Y, Hu J, Chen Y, Yu T and Hu L. Silencing MARCH1 suppresses proliferation, migration and invasion of ovarian cancer SKOV3 cells via downregulation of NF-kappaB and Wnt/beta-catenin pathways. Oncol Rep 2016; 36: 2463-2470.
39. Doppler H, Panayiotou R, Reid EM, Maimo W, Bastea L and Storz P. The PRKD1 promoter is a target of the KRas-NF-kappaB pathway in pancreatic cancer. Sci Rep 2016; 6: 33758.
40. deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW and Weiss GR. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2004; 15: 885-890.
41. Nomura A, Majumder K, Giri B, Dauer P, Dudeja V, Roy S, Banerjee S and Saluja AK. Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer. Lab Invest 2016; 96: 1268-1278.
42. Dror R, Lederman M, Umezawa K, Barak V, Pe'er J and Chowers I. Characterizing the involvement of the nuclear factor-kappa B (NF kappa B) transcription factor in uveal melanoma. Invest Ophthalmol Vis Sci 2010; 51: 1811-1816.
43. Son SW, Kim HG, Han JM, Lee JS, Choi MK, Lee JS and Son CG. Anti-melanoma activity of Cynanchi atrati Radix is mediated by regulation of NF-kappa B activity and pro-apoptotic proteins. J Ethnopharmacol 2014; 153: 250-257.
44. Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, Nguyen T and Hersey P. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 2001; 166: 5337-5345.